This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Discovery, Selection and Screening
September 27-29 2021
Webcast Series

Julia Tietz
Associate Director at Numab Therapeutics AG


Julia leads the Bioanalytics group at Numab Therapeutics, an emerging Swiss biotech company developing multiple immuno-oncology programs utilizing the versatile, multi-specific MATCH platform. In this position, she is responsible for the development of ELISA, cell-based and biomarker assays and leads a preclinical discovery project in the field of inflammation. Prior to joining Numab, Julia held a Team Leader position at ESBATech, a Novartis company, where she significantly contributed to the discovery and preclinical characterization of the VEGF inhibitor Beovu, a humanized single chain antibody recently approved by the FDA. Julia holds an MSc in Biology from the University of Neuchâtel, Switzerland.

Agenda Sessions

  • Advancement of Multispecific MATCH Antibodies as Novel Therapeutics with Disease Modulating Functions and the Potential for Favorable Benefit-risk Profiles


Speakers at this event